EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtMetaanalyseOpen Access

Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis

Herman Johal, Tahira Devji, Yaping Chang iD, Jonathan Simone, Christopher Vannabouathong iD, Mohit Bhandari

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders · 2020-01 · 13 · 117954412090646

DOI: 10.1177/1179544120906461 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, online erschienen am 19.02.2020. Verfasst von Herman Johal und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center for Evidence-Based Orthopaedics, Division of Orthopaedics, Department of Surgery, McMaster University, Hamilton, ON, Canada. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For patients with chronic, non-cancer pain, traditional pain-relieving medications include opioids, which have shown benefits but are associated with increased risks of addiction and adverse effects. Medical cannabis has emerged as a treatment alternative for managing these patients and there has been a rise in the number of randomized clinical trials in recent years; therefore, a systematic review of the evidence was warranted.

Objective

To analyze the evidence surrounding the benefits and harms of medical cannabinoids in the treatment of chronic, non-cancer-related pain.

Design

Systematic review with meta-analysis. Data sources: Medline, Embase, CINAHL, SCOPUS, Google Scholar, and Cochrane Databases. Eligibility criteria: English language randomized clinical trials of cannabinoids for the treatment of chronic, non-cancer-related pain. Data extraction and synthesis: Study quality was assessed using the Cochrane risk of bias tool. All stages were conducted independently by a team of 6 reviewers. Data were pooled through meta-analysis with different durations of treatment (2 weeks, 2 months, 6 months) and stratified by route of administration (smoked, oromucosal, oral), conditions, and type of cannabinoids. Main outcomes and measures: Patient-reported pain and adverse events (AEs).

Results

Thirty-six trials (4006 participants) were included, examining smoked cannabis (4 trials), oromucosal cannabis sprays (14 trials), and oral cannabinoids (18 trials). Compared with placebo, cannabinoids showed a significant reduction in pain which was greatest with treatment duration of 2 to 8 weeks (weighted mean difference on a 0-10 pain visual analogue scale −0.68, 95% confidence interval [CI], −0.96 to −0.40, I 2 = 8%, P < .00001; n = 16 trials). When stratified by route of administration, pain condition, and type of cannabinoids, oral cannabinoids had a larger reduction in pain compared with placebo relative to oromucosal and smoked formulations but the difference was not significant ( P[interaction] > .05 in all the 3 durations of treatment); cannabinoids had a smaller reduction in pain due to multiple sclerosis compared with placebo relative to other neuropathic pain ( P[interaction] = .05) within 2 weeks and the difference was not significant relative to pain due to rheumatic arthritis; nabilone had a greater reduction in pain compared with placebo relative to other types of cannabinoids longer than 2 weeks of treatment but the difference was not significant ( P[interaction] > .05). Serious AEs were rare, and similar across the cannabinoid (74 out of 2176, 3.4%) and placebo groups (53 out of 1640, 3.2%). There was an increased risk of non-serious AEs with cannabinoids compared with placebo.

Conclusions

There was moderate evidence to support cannabinoids in treating chronic, non-cancer pain at 2 weeks. Similar results were observed at later time points, but the confidence in effect is low. There is little evidence that cannabinoids increase the risk of experiencing serious AEs, although non-serious AEs may be common in the short-term period following use.

Schlagwörter

Stichwörter der Autor:innen

Cannabinoidschronic painmultiple sclerosis

Autor:innen und Institutionen

  • Center for Evidence-Based Orthopaedics, Division of Orthopaedics, Department of Surgery, McMaster University, Hamilton, ON, Canada.
  • OrthoEvidence Inc., Burlington, ON, Canada.
  • Aphria Inc., Leamington, ON, Canada.

ORCID-Profile: Yaping Chang, Christopher Vannabouathong

Zitieren

APA

Johal, H., Devji, T., Chang, Y., Simone, J., Vannabouathong, C., & Bhandari, M. (2020). Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 13, 117954412090646. https://doi.org/10.1177/1179544120906461

Vancouver

Johal H, Devji T, Chang Y, Simone J, Vannabouathong C, Bhandari M. Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders. 2020;13:117954412090646. doi:10.1177/1179544120906461

BibTeX
@article{Johal2020,
  author = {Johal, Herman and Devji, Tahira and Chang, Yaping and Simone, Jonathan and Vannabouathong, Christopher and Bhandari, Mohit},
  title = {Cannabinoids in Chronic Non-Cancer Pain: A Systematic Review and Meta-Analysis},
  journal = {Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders},
  year = {2020},
  volume = {13},
  pages = {117954412090646},
  doi = {10.1177/1179544120906461}
}
Kostenlos starten →